SAN DIEGO--(BUSINESS WIRE)--Aug. 28, 2006--Inovio Biomedical Corporation (AMEX:INO) announced today that its partner, Tripep AB of Sweden, has achieved additional positive pre-clinical results showing that its ChronVac-C DNA vaccine combined with Inovio’s MedPulser(R) DNA delivery system produced a strong immune response against hepatitis C virus (HCV) in a large animal model. Ongoing toxicity studies of ChronVac-C(R) delivered using Inovio’s electroporation-based system revealed that the combination induces a humoral response in rabbits that is comparable to results previously observed in mice.
